Public Health News Roundup: December 22
An experimental HIV vaccine based on a genetically modified killed whole virus has received approval by the Food and Drug Administration to start human clinical trials. The Phase I trial, beginning in January, will double check the safety of the vaccine in humans and will include 40 volunteers with HIV. The next phase will test immune response in 600 high-risk HIV-negative volunteers. According to the researchers, previous efforts to create HIV vaccines have used certain genes or proteins from the virus. The new vaccine uses the whole HIV virus, which has been genetically engineered to prevent it from infecting recipients. The researchers say the vaccine is designed to prime the body's T-cells to destroy any cells that might become infected with the HIV virus. Read the latest news on HIV developments.
McNeil Consumer Healthcare is voluntarily recalling certain lots of MOTRIN® IB 24 count coated caplets, 24 count coated tablets and 24+6 count coated caplets from stores. The company says this is not a consumer-level recall, which means that consumers do not need to dispose of or return the product. There is no safety concern if consumers continue taking the product as directed on the label, but it is possible there may be a delay in experiencing pain relief. Read up on prescription drug news.
The company says it is recalling these products because testing of product samples showed that some caplets may not dissolve as quickly as intended when nearing their expiration date.
A study in the journal Gut finds that cases of acid reflux have risen by almost 50 percent in the last ten years. In addition to the painful symptoms and cost of treatment, acid reflux can lead to cases of esophageal cancer, according to the study authors. Read more on obesity.